Browsing by Author Gish, RG

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 10 to 23 of 23 < previous 
TitleAuthor(s)Issue DateViews
 
Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B
Journal:Journal of Viral Hepatitis
Gish, RGChang, TTLai, CLDe Man, RGadano, APoordad, FYang, JBrettSmith, HTamez, R
2010
91
 
Loss of HBsAg in nucleoside-naive HBeAg(+) chronic hepatitis B patients following treatment with entecavir or lamivudine: evaluation of HBV genotypes
Proceeding/Conference:Hepatology
Gish, RGChang, TTLai, CLDe Man, RAPoordad, FXu, DBrett-Smith, HHarris, MIloeje, UTang, H
2009
59
 
Predicting HBsAg clearance responses during ARC-520 RNA interference (RNAi) therapy based on HBsAg epitope profile analysis
Proceeding/Conference:Journal of Hepatology
Walsh, RYuen, LHammond, RDeerain, JGiven, BSchluep, TYuen, MFChan, HLYLai, CLHamilton, JLau, JYFerrari, CGish, RGLocarnini, SA
2016
69
 
Prolonged RNA interference therapy with ARC-520 Injection in treatment naïve, HBeAg positive and negative patients with chronic HBV results in significant reductions of HBs antigen
Proceeding/Conference:Journal of Hepatology
Yuen, RMFLiu, SHKChan, HLYGiven, BDSchluep, THamilton, JLai, CLLocarnini, SALau, JYFerrari, CGish, RG
2017
63
 
Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive, nucleoside-naive patients treated with entecavir
Journal:Antiviral Therapy
Gish, RGChang, TTLai, CLde Man, RAGadano, ALlamoso, CTang, H
2013
35
 
RNA Interference Therapy With ARC‐520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection
Journal:Hepatology
Yuen, MFSchiefke, IYoon, JHAhn, SHHeo, JKim, JHChan, HLYYoon, KTKlinker, HManns, MPetersen, JSchluep, THamilton, JGiven, BDFerrari, CLai, CLLocarnini, SAGish, RG
2020
20
 
RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg
Journal:Science Translational Medicine
Wooddell, CIYuen, RMFChan, HLYGish, RGLocarnini, SAChavez, DFerrari, CGiven, BDHamilton, JKanner, SBLai, CLLai, JYNSchluep, TXu, ZLanford, RELewis, DL
2017
32
 
Safety, Tolerability, and Pharmacokinetics of ARC-520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers
Journal:Clinical Pharmacology in Drug Development
Schluep, TLickliter, JHamilton, JLewis, DLLai, CLLau, JYNLocarnini, SAGish, RGGiven, BD
2017
43
 
Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and baseline factors
Proceeding/Conference:Journal of Hepatology
Gane, ELocarnini, SLim, THStrasser, SSievert, WCheng, WThompson, AGiven, BSchluep, THamilton, JBiermer, MKalmeijer, RBeumont-Mauviel, MLenz, ODe Ridder, FCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RGYuen, RMF
2021
44
 
Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg < 100 IU/ml threshold
Proceeding/Conference:Journal of Hepatology
Yuen, RMFLocarnini, SLim, THStrasser, SSievert, WCheng, WThompson, AGiven, BSchluep, THamilton, JCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RGGane, E
2019
73
 
Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen suppression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment
Proceeding/Conference:Journal of Hepatology
Gane, ELocarnini, SLim, THStrasser, SSievert, WCheng, WThompson, AGiven, BSchluep, THamilton, JBiermer, MKalmeijer, RBeumont-Mauviel, MLenz, OCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RGYuen, RMF
2020
78
 
Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent
Journal:Antiviral Research
Gish, RGYuen, RMFChan, HLYGiven, BDLai, CLLocarnini, SALau, JYNWooddell, CISchluep, TLewis, DL
2015
48
 
T1653 mutation in the box α increases the risk of hepatocellular carcinoma in patients with chronic hepatitis B virus genotype C Infection
Journal:Clinical Infectious Diseases
Ito, KTanaka, YOrito, ESugiyama, MFujiwara, KSugauchi, FKato, TTokita, HIzumi, NKato, MYuen, MFLai, CLGish, RGUeda, RMizokemi, M
2006
138
 
Three-year assessment of entecavir resistance in chronic hepatitis B patients and the mechanism of viral breakthrough by the resistance substitutions
Proceeding/Conference:Hepatology
Tanaka, YMukaide, MYuen, RMFShin, ITOrito, EKurbanov, FFukai, KYokosuka, OSata, MIde, TKarino, YYamada, GSakaguchi, KInoue, MGish, RGLai, CLMizokami, M
2008
127
Showing results 10 to 23 of 23 < previous